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Abstract
Background: Ulcerative colitis (UC) harbours a high risk of UC-associated colorectal cancer (UCCC), which is
important cause of morbidity and mortality in patients with inflammatory bowel disease. Overall Survival (OS) of
patients with UCCC has not been addressed well in the literature. Thus, we compared oncologic outcome of UCCC
and sporadic colorectal cancer (SCC) using propensity score matching analysis.
Methods: Propensity score matching was performed for 36 patients, a 1:1 matching method stratified into 18 in UCCC
and 18 patients in SCC. Matched variables were sex, age, body mass index, tumour stage, histology, preoperative
carcinoembryonic antigen (CEA) level, and adjuvant treatment status. Patients with SCC or UCCC were retrospectively
retrieved from our database from March 2000 to December 2015. All patients had undergone either oncological
segmental resection or total proctocolectomy.
Results: The majority of cancers were found in the sigmoid colon. Total proctocolectomy was performed only in
the UCCC group; however, half of the UCCC group underwent a standard operation. Five cases of postoperative
complication occurred within six months in the UCCC group compared to one case in the SCC group. There was no
significant difference in recurrence rate (p = 0.361) or OS (p = 0.896) between the arms.
Conclusion: UCCC showed more postoperative complications than SCC, and equivalent oncology outcome, however
the difference was not statistically significant. This study represents an experience of a single institution, thus further
randomized studies are required to confirm our.
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Background
Ulcerative colitis (UC) is a chronic inflammatory disease
of the large bowel for which the aetiology is not fully
understood [1]. This disease harbours a high risk of
associated colorectal cancer (UCCC). This is the most
important cause of morbidity and mortality in patients
with inflammatory bowel disease (IBD) [2], accounting
for 10-15% of deaths in IBD patients [3]. However, the
real impact of colorectal cancer (CC) is still debated in
the literature. Fifteen years ago, Eaden et al. published a
meta-analysis reporting that the cumulative risk of CC
in patients with UC was 2% at 10 years [4]. A later
meta-analysis by Lutgens et al. reviewed eight studies
published from 1988 to 2009 and showed that the risk of
CC was increased in IBD but was not as high as
reported in earlier studies; the pooled standardised
incidence rate in their study was 1.7 [5]. Recently,
Castano-Milla and colleagues published their systemic
review and meta-analysis [6], in which they concluded
that the risk of developing CC among patients with UC
has decreased steadily over the last six decades and was
1.58 per 1,000 patient-years. Another recent meta-analysis
showed a 2.4-fold higher rate of CC in UC patients
compared to the overall population [7].
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Previous studies have reported several clinical and
pathogenetic differences between sporadic CC (SCC)
and UCCC. It is known that CC occurs about 30 years
earlier than UCCC in UC patients [4]. UC patients are
known to have higher rates of multifocal, right-sided
tumours and mucinous or signet ring cell carcinomas,
which are associated with poor prognosis [8, 9].
The survival of patients with UCCC was not discussed
in previous reports. Early studies showed five -year
survival rates up to 30% [10–13]; however, the overall
survival (OS) for patients with SCC at the same period
was similar. Recent studies have shown much higher
survival rates and no significant difference between
UCCC and SCC patients [14]. In contrast, some other
studies have reported poorer survival for UCCC patients
than for patients with SCC [8, 15–18]. The authors ex-
plained the poorer survival in UCCC patients by an un-
favourable stage distribution, since a greater proportion
of UCCC patients had distant metastasis at the time of
cancer diagnosis. The existing data are conflicting and
heterogeneous, as patient collectives vary regarding fac-
tors such as follow-up period, matching criteria, and
stage distribution.
Because of the relatively low prevalence, little is known
about the differences in prognosis between SCC and
UCCC. In this study, we compared two cohorts of
UCCC and SCC patients in terms of long-term outcome
and recurrence rate using propensity score matching
analysis.
Methods
Patients
Data for all patients who underwent surgical treatment for
UCCC and SCC in the Department of Surgery at Yonsei
University between March 2000 and December 2015 were
collected retrospectively. All patients diagnosed with
colon cancer due to sporadic or ulcerative colitis have
been enrolled in our analysis. However, to achieve an ac-
curate analysis we carried out propensity cross match ana-
lysis. A total of 36 patients divided according to aetiology
of colon cancer into 18 patients by UCCC and 18 patients
were SCC. All patients have been matched following these
criteria: age at surgery (±5 years), sex, body mass index
(BMI), tumour stage (according to American joint com-
mission for cancer), histology, preoperative CEA level, and
adjuvant treatment. Patient demographics, co-morbidities,
detailed operative information, histopathologic tumour
features, and follow-up data were obtained by medical rec-
ord review. The primary outcome for comparison was OS.
Recurrent disease was defined if a suspected lesion
became apparent by imaging modalities after a period of
6 months of undetectable disease, including local recur-
rence in the same location as the primary tumour, regional
recurrence, and distant recurrence in other organs such as
liver and lungs. Board-certified colon and rectal sur-
geons at a tertiary referral centre participated in per-
forming designed surgery. Resections for CC included
segmental proctectomy or extended resection by total
proctocolectomy.
Statistical analysis
Categorical variables are expressed as percentage and com-
pared by Fisher’s exact test or Chi-square test as appropri-
ate. Continuous variables are presented as mean ± standard
error of the mean or median and interquartile range (IQR)
per group and are compared using two-tailed Student’s
t-test. Survival curves for 1, 3, 5, and 10 years were gener-
ated using the Kaplan-Meier method, and survival was
compared by log rank and Breslow tests. Survival percent-
ages per measured time point are reported with 95% con-
fidence interval (CI). Significance was set at p < 0.05.
Calculations were performed using SPSS Statistics for
Windows.
Results
Out of 36 patients, 18 (50%) had SCC and 18 (50%) had
UCCC. Patient characteristics of BMI, age, sex, patho-
logical stage, preoperative CEA level, and tumour location
were matched in both groups (Table 1). Adjuvant chemo-
therapy was administered equally to both groups. The ma-
jority of cancers were found in the colon: 15 (83.3%) for
each of SCC and UCCC. Most patients in the SCC group
presented with stage II cancer (9 patients, 50%), whereas
in the UCCC group, 6 patients (33.3%) had stage II and 7
(38.9%) had stage III disease. Total proctocolectomy was
performed significantly more often in the UCCC group
(9 vs. 0 patients, p = 0.001). UCCC showed more postop-
erative complications than SCC (5 vs. 1), although this
was not significant (p = 0.634). A relatively higher local re-
currence rate was observed in SCC (5.6% [1 patient] vs. 0
in the UCCC group), but the overall recurrence was not
significantly differ (p = 0.361) (Table 2). There was no sig-
nificant difference in five-year OS between the two arms
(Fig. 1).
Discussion
In this study, we compared the prognosis of patients
with UCCC or SCC in a matched pair analysis that
including one of the largest cohorts of UCCC patients to
date [14]. Prognosis was similar in the two groups, with
a trend toward higher recurrence rate in the SCC group.
UCCC patients are typically younger and more fre-
quently have multiple cancerous lesions and a macro-
scopically permeating pattern of spread, including
mucinous or signet ring cell carcinomas, compared with
SCC. The advanced stage at presentation results in a less
favourable outcome for UCCC patients [2, 7, 8].
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Chronic inflammation leads to the activation of
sequins, which in turn leads to CC in UC patients.
Colonic mucosa in UC exhibits high levels of chromo-
somal abnormalities clustered in regions of histological
abnormality, and genomic derangements are a promin-
ent feature of preinvasive neoplasia [1]. The same gen-
etic and signalling pathways involving Wnt, β-catenin,
K-ras, p53, and transforming growth factor (TGF)-β can
be found in SCC and UCCC; however, a difference in
activation timing between SCC and UCCC has been
reported [3]. Mutations in p53 occur early in the
adenoma-carcinoma sequence and are often detected in
non-dysplastic or indefinite dysplasia in UC, whereas
p53 mutations occur in the late phase in sporadic aden-
oma [19]. Microsatellite instability (MSI) is also rela-
tively frequent in non-dysplastic inflamed epithelia, and
transforming growth factor β receptor type II (TGFβRII)
is one of the genes targeted by the MSI process in
UCCC. Hypermethylation of hMLH1, p16INK4a, and
p14ARF seems to precede dysplasia and contribute to
the genetic alterations in UCCC [20]. Kinugasa et al. also
showed that expression of claudin-1 was increased in
UCCC and dysplasia compared with normal mucosa and
is likely to be involved in neoplastic progression in UC
patients [21].
Some previous studies have shown worse oncological
outcomes in the UCCC patient group [8, 18, 22]. In a
Japanese nationwide study, Watanabe et al. assessed 121
patients who had undergone surgery for UCCC. They
found that, compared with patients with SCC, those
with UCCC were younger and had a higher proportion
of multiple cancer lesions, higher proportions of
morphologically superficial type lesions and invasive type
lesions, and higher proportions of mucinous or signet
ring cell carcinomas. For stage III disease, patients with
UCCC had a poorer survival rate than those with SCC
(43.3% versus 57.4%, P = 0.0320); however, the OS was
similar in earlier stages [8]. The UCCC-specific factors
and different clinicopathologic patterns mentioned
above are thought to result in an unfavourable prognosis
[8, 23–25]. In a Danish cohort study by Jensen et al. 279
UCCC patients were compared to 71,259 SCC patients.
The OS was significantly worse in the UCCC group. The
negative effect of UC on the prognosis of CC was more
pronounced in the first year after cancer diagnosis, in
patients diagnosed with CC before the age of 70 years,
in patients with UC duration of eight years or more, and
in cancers with advanced or unknown stage [18]. In a re-
cent matched pair analysis, 33 patients with inflamma-
tory bowel disease-associated CC had a significantly
reduced and markedly lower OS rate, as well as a not-
ably increased recurrence rate, compared to sporadic
Table 2 Operative variables and short- and long-term results of
patients undergoing colonic or rectal resection
Variables Sporadic CC (n = 18) UCCC (n = 18) P value
Operation method 0.735
Open 8 (44.4%) 7 (38.9%)
MIS 10 (55.6%) 11 (61.1%)
Operation name 0.001
Total proctocolectomy
with end ileostomy
0 (0%) 1 (5.6%)
Total proctocolectomy with
J-pouch anal anastomosis
0 (0%) 4 (22.2%)
Total proctocolectomy with
ileo-anal anastomosis
0 (0%) 4 (22.2%)
Others 18 (100%) 9 (50%)
Complication 0.624
Obstruction 1 (5.6%) 4 (22.2%)
Rectovaginal fistula 0 (0%) 1 (5.6%)
Recurrence 0.361
Local 1 (5.6%) 0 (0%)
Systemic 2 (11.1%) 2 (11.1%)
All values are represented as n (%)
MIS minimal invasive surgery, UC ulcerative colitis, UCCC ulcerative colitis-related
colorectal cancer
Table 1 Characteristics and perioperative findings of patients
diagnosed with colorectal cancer
Variables Sporadic (n = 18) UC (n = 18) P-value
Age at surgery (years) 52 (30–73) 51 (31–68) 0.866
Sex 0.735
Male 7 (38.9%) 8 (44.4%)
Female 11 (61.1%) 10 (55.6%)
BMI (kg/m2) 23.23 ± 3.36 22.38 ± 1.47 0.328
Stage 0.593
1 4 (22.2%) 5 (27.8%)
2 9 (50%) 6 (33.3%)
3 5 (27.8%) 7 (38.9%)
Adjuvant chemotherapy 1.0
Yes 12 (66.7%) 12 (66.7%)
No 6 (33.3%) 6 (33.3%)
Histology 0.388
WD 3 (16.7%) 5 (27.8%)
MD 13 (72.2%) 9 (50%)
PD 2 (11.1%) 4 (22.2%)
Carcinoembryonic
antigen (CEA)
2.27 ± 2.28 2.55 ± 1.79 0.684
Location 1.0
Rectum 3 (16.7%) 3 (16.7%)
Colon 15 (83.3%) 15 (83.3%)
All values are represented as n (%) or mean ± SD
UC ulcerative colitis, WD well differentiated, MD moderately differentiated,
PD poorly differentiated
Han et al. BMC Surgery  (2017) 17:28 Page 3 of 6
CRC patients (48.6 vs. 67.1%, respectively) [22]. A
single-centre retrospective study performed in 2016
compared OS and surgical technique in 27 patients with
UC and rectal cancer and 54 patents with sporadic rectal
cancer [14]. UCCC patients undergoing proctectomy dem-
onstrated reduced disease-free survival (DFS) compared
with those undergoing proctocolectomy and patients with
sporadic rectal cancer undergoing proctectomy. The
authors concluded that proctocolectomy should be consid-
ered the preferred surgical approach for colitis-associated
rectal cancer.
Our study and some other retrospective single-centre
studies showed no difference in OS [17, 26–28]. Our
study was in agreement with the survival results of a
Finnish study from 1998 that compared 33 UCCC
patients to 122 patients with non-UCCC [17]. In two
smaller retrospective case-matched cohort studies per-
formed in a single tertiary centre by Kiran et al. [26] and
Delaunoit et al. [27], the authors found no difference in
OS between patients with IBD and CC with those with
SCC. In a later study by Delaunoit, higher tumour
grades and mucinous differentiation were more frequent
among patients with UCCC. Kiran et al. [26] found no
difference between two groups of UCCC and SCC
patients in terms of local recurrence, DFS, or OS. In a
recent large study from Germany, the authors matched
UCC and SCC patients 1:1 [28]. Although they found
more of the above mentioned risk factors in the UCCC
group, the oncological outcome was the same in both
groups. In a subgroup analysis of UCCC patients, female
sex was associated with a significantly better prognosis.
The authors assumed that oestrogens play a protective
role in UCCC carcinogenesis.
Interestingly, some population-based studies have
shown decreased mortality in patients with UCCC com-
pared to those with UC. The authors explain this finding
by long-term usage of 5-ASA [29]. The same study
showed an increased risk of postoperative complications
(postoperative deaths, septicaemia, other abdominal
infections) in patients with UCCC. However, our study
did not show any significant differences in the rate of
complications.
Although total proctocolectomy with ileal pouch-anal
anastomosis is the gold standard for UCCC, the pros and
cons of rectal mucosectomy are still debated [30].
Whether this represents the optimal procedure for UC
Fig. 1 Kaplan–Meier estimates of overall survival and 5- and 10-year overall survival rates of 18 patients with ulcerative colitis-associated carcinoma
and 18 patients with sporadic colorectal carcinoma. SCC – sporadic colorectal cancer; UCCC – ulcerative colitis-related colorectal cancer
SCC 114.05 ± 11.13, 95% CI (92.23 – 135.87) UCCC 147.89 ± 18.55, 95% CI (111.53 – 184.24) Log rank: p = 0.896 Breslow: p = 0.932
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patients with SCC remains questionable, as the functional
quality of life differs substantially between patients with
proctocolectomy and those with partial resection. In eld-
erly patients with poor anal function, surgical procedures
should obviously be selected based on overall consider-
ations including prognosis of the cancer, degree of inflam-
mation with colitis, and potential requirements for future
treatment. Uchino et al. have reported two cases with mild
inflammation that underwent segmental colon resection
[31]. Some case reports even show the usefulness of prog-
nostic factors for the possibility of segmental resection [5].
Recent studies have shown the importance of sur-
veillance programs in patients with long lasting UC
[32, 33]. The authors concluded that colonoscopy results
in diagnosis of cancer at earlier stages and younger ages.
In addition, premalignant conditions can also be identified
[32]. Most international guidelines recommend surveil-
lance for UC using colonoscopy every 1-2 years over 8-10
years after the onset of UC diagnosis [34–39].
Our study has some limitations. First, the single
centre, relatively small size, and retrospective nature of
the study might weaken the significance of our findings.
Second, there may be selection bias because not all pa-
tients who were diagnosed with UC and CC in the study
period were included in the study, although we per-
formed matched analysis for patient sex, age, body mass
index, tumour stage, histology, preoperative CEA level,
and adjuvant treatment status.
Conclusion
In conclusion, our data suggest that patients with UCCC
have the same prognosis as patients with SCC. All other
factors related to UC (e.g., UC treatment before and after
CC, disease activity and duration) and CC (e.g., aggressive
tumours, surgical techniques, and surgical complications),
as well as a number of other factors should be investigated
in order to rule out confounding factor that might be of
prognostic value (e.g., co-morbidity, co-medication, her-
editary factors). Therein, well clinical trial is required to
address this on going debates in the future.
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